Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07169825 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Name: Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function — clinical trial record (NCT07169825)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorM.D. Anderson Cancer Center

Started2026-03-30

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 4, 2026 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-07-31

Study Status, Study Design v3

Phase changed: not applicable → Phase 4

2026-03-31

Study Status, Contacts/Locations v2

Recruitment opened

Start dateestimated 2026-08-13→confirmed 2026-03-30

Study sitesdetails revised at 1 of 1 site

2026-03-06

Study Status v1

Start date2026-02-13→2026-08-13

2025-09-05

Original filing

M.D. Anderson Cancer Center

1,223 trials monitored

See 78 trials at risk

To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.

Trial Details

NCT Number	NCT07169825
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: GE Healthcare
Conditions	Lu-177 PSMA
Enrollment	25 participants
Start Date	2026-03-30
Primary Completion	2026-09-01 (estimated)
Study Completion	2028-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-04